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Abstract
Background: Antiretroviral treatment (ART) has reduced morbidity 
and mortality due to AIDS. However, treatment options can be im-
paired by the development of antiretroviral drug resistance. Resistant 
virus strains can be transmitted to new hosts and, subsequently, can 
lead to antiretroviral treatment failure.
Methods: Th A systematic review of articles on resistance to antire-
troviral therapy for HIV-infected individuals, published from January 1, 
2014 to June 16, 2014, on SCOPUS and PUBMED databases wascarried 
out. Search terms were "AIDS" (Medical Subject Headings [MeSH]), 
"HIV" (MeSH), “treatment” (keyword), “resistance” (keyword) and 
"antiretroviral therapy" (MeSH). Of the 118 retrieved studies, 24 met 
the eligibility criteria.
Results: The main classes of antiretroviral drugs are Non Nucleoside 
Reverse Transcriptase Inhibitors (NNRTIs), Nucleoside Reverse Trans-
criptase Inhibitors (NRTIs), and Protease Inhibitors (PIs). Antiretroviral 
treatment selects for drug resistance. Resistant strains become preva-
lent in the population and are transmitted to new patients.
Discussion: A higher prevalence of certain mutations are present 
and characterize resistant strains that are prevalent in the population 
making it more difficult to treat these infected individuals. Poor com-
pliance with antiretroviral therapy increases the potential for develo-
ping these and other resistant strains.
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Introduction 
The wide use of combination antiretroviral therapy 
(cART), for example, succeeded in sustained inhibi-
tion of viral replication and reduced significantly the 
morbidity and mortality of HIV related disease. [1-5] 
However, treatment options have been impaired by 
the development of antiretroviral drug resistance. 
Resistant virus strains can develop in a patient but 
are likely to be acquired from others leading to an-
tiretroviral treatment failure. [6, 7] 
Antiretroviral therapy resistance is a concern not 
just for individual patients, but also for society due 
to the high potential transmission of drug-resistant 
HIV. This compromises the effectiveness of availa-
ble first-line regimens for a substantial portion of 
the population and increases the need for costly 
second-line drugs. [8] 
This study is based on the following research 
questions: what are the main mutations conferring 
resistance to antiretroviral treatments and how do 
individuals acquire resistant strains? This issue has 
gained great impact in recent years with the cons-
tant and intense research on the many HIV antire-
troviral therapies. Thus, this systematic review aims 
to present the main classes of drugs for ART and 
the resistance mechanisms that could lead to anti-
retroviral treatment failure. 
Methods 
We performed a qualitative systematic review of 
articles about the resistance to antiretroviral drugs 
used to treat HIV/AIDS in previously chosen electro-
nic databases. 
A search of the literature was conducted via Pub-
Med and SCOPUS online databases in June 2014 
and was limited to articles published from January 
1, 2014 to June 16, 2014. The reason for limiting 
the search to 2014 was that several studies on the 
subject of HIV and resistance to antiretroviral the-
rapies are performed every year, being necessary to 
recovery most recent data on resistance to antire-
troviral drugs. Initially, the search terms browsed in 
SCOPUS database were: 
1.  "AIDS" (Medical Subject Headings [MeSH] 
term); 
2.  “HIV” ([MeSH]) 
3.  “treatment” (keyword). 
4.  “resistance” (keyword); and 
5.  “antiretroviral therapy” ([MeSH]) 
The following searches were performed: 1 OR 2 
AND 3 AND 4 AND 5. In addition to MeSH terms, 
we opted to add the keywords "treatment" and 
“resistance” to the search strategy, because, despite 
not being included in the MeSH thesaurus, they are 
frequently used to describe studies that deal with 
the theme object of the present review. The search 
strategy and the retrieved articles were reviewed on 
two separate occasions to ensure adequate sam-
pling. A similar search strategy was performed in 
the PubMed database, using the aforementioned 
terms and their correspondent terms. 
The article analysis followed previously determined 
eligibility criteria. We adopted the following inclusion 
criteria: (1) references written in English; (2) studies 
pertaining resistance to antiretroviral therapy for HIV-
infected individuals; (3) original articles with online 
accessible full text available in database SCOPUS, 
Conclusions: Knowledge of drug resistance generated by muta-
tions is useful for optimizing treatment regimens and to get better 
responses. Promoting compliance is important to limiting the selec-
tion of new resistant strains.
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PubMed or CAPES (Higher Education Co-ordination 
Agency) Journal Portal9, a virtual library linked to 
Brazil’s Ministry of Education and subjected to con-
tent subscription; (4) articles that included in the title 
at least one combination of terms described in the 
search strategy; (5) case reports, descriptive studies, 
cross-sectional studies, cohort studies, controlled cli-
nical trials and case-control studies; (6) articles that 
appear in more than one database will be included 
only once, giving priority to the SCOPUS database. 
Exclusion criteria were: (1) studies that did not in-
clude the proposed topic; (2) non-original studies, 
including editorials, reviews, prefaces, brief commu-
nications and letters to the editor. 
Then, each paper in the sample was read in en-
tirety, and data elements were then extracted and 
entered into a matrix that included authors, journal, 
description of the study sample, and main findings. 
This study did not require an assessment of an 
ethics committee because it is a systematic review. 
Similarly, for the same reason, this manuscript did 
not involve patient consent. The study was conduc-
ted based on literature obtained according to our 
inclusion criteria. 
 
Results 
Initially, the aforementioned search strategies resul-
ted in 118 references. After browsing the title and 
abstract of the retrieved citations for eligibility based 
on study inclusion criteria, 91 articles were excluded 
and 27 articles were further retrieved and included 
in the final sample (Figure 1). Articles from SCOPUS 
and PubMed database matched the inclusion crite-
ria of the present study. 
Table 1 provides an overview of all studies inclu-
ded in the final sample and of all data elements 
Figure 1: Flow diagram of study.
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Table 1.  Resistance to antiretroviral therapy for HIV-infected individuals: studies and main findings.
Journal Sample Sample Study Particularities
Drescher, 
SM. Et al. [1]
Clinical 
Infectious 
Diseases
ART-naive men who have sex with men with 
infection date estimates between 1996 and 2009 
(1674).
Many individuals harboring viral TDR belonged to transmission clusters with other Swiss patients, indicating 
substantial domestic transmission of TDR in Switzerland. Most TDR in clusters could be linked to sources, 
indicating good surveillance of TDR in the SHCS-DRDB. Most TDR sources were ART naive. This, and the 
presence of long TDR transmission chains, suggests that resistance mutations are frequently transmitted 
among untreated individuals, highlighting the importance of early diagnosis and treatment.
Zu 
Knyphausen, 
F.et al. [7]
PLoS ONE Data of 1,667 HIV-infected individuals who 
seroconverted between 1996 and 2010 were 
analysed.
 Overall prevalence of TDR remained stable at a rather high level. No significant differences in the frequency 
of virologic failure were identified during first-line cART between patients with TDR and fully-active cART, 
patients with TDR and nonfully active cART and patients without TDR. 
Cambiano, 
V. et al. [8]
AIDS We estimate 652 000 people (90% uncertainty 
range: 543 000-744 000) are living with 
nonnucleoside reverse transcriptase inhibitor 
(NNRTIs)-resistant virus in South Africa, 275 000 in 
majority virus [Non-nucleoside reverse transcriptase 
inhibitor resistant virus present in majority virus 
(NRMV)] with an unsuppressed viral load.
Prevalence of resistance is projected to increase substantially. However, introduction of policies to increase 
ART coverage is not expected to lead to appreciably higher prevalence of HIV positive people with resistance 
and viral load more than 500 copies/ml. Concern over resistance should not stop expansion of treatment 
availability. 
Fall-Malick, 
F-Z et al. 
[10]
Journal of 
Medical 
Virology
Eighty-six subjects were included and 65 samples 
were amplified successfully and sequenced.
Phylogenetic analysis revealed 17 HIV-1 variants with the predominance of CRF02_AG (n=42; 64.6%). A high 
rate of DRM was found in this study and shows the potential need for a structured virological surveillance 
including viral load quantification and genotyping. Further studies may also be needed in regards to the great 
variability of HIV-1 strains in Mauritania. 
Mulu, A. et 
al. [15]
BMC 
Infectious 
Diseases
Consecutive HIV-1 infected adults (N = 100) and 
children (N = 100) who have been receiving ART 
for up to 6 years at Gondar University Hospital, 
Ethiopia.
Majority of both adults (82%) and children (87%) who received ART showed high viral suppression and 
immunological recovery. This indicates that despite limited resources in the setting virological efficacy can 
be sustained for a substantial length of time and also enhance immunological recovery irrespective of age. 
However, the presence of drug resistance mutations and low level viraemia among clinically asymptomatic 
patients highlights the need for virological monitoring.
Baesi, K. et 
al. [17]
Journal of 
Medical 
Virology
All 30 participants naïve to ART and 62 of 70 
(88.6%) participants receiving ART had detectable 
viral loads.
These findings document an alarmingly high frequency of multiple HIV drug class resistance in Iran, confirm the 
presence of TDR, and highlight the need for systematic viral load monitoring and drug resistance testing, including 
at diagnosis. Expanded access to new antiretroviral medications from additional drug classes is needed.
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Journal Sample Sample Study Particularities
Azam, M. et 
al. [21]
Archives of 
Virology
Drug resistance genotyping of a partial reverse 
transcriptase gene was done in 103 HIV-1-infected 
patients.
Major amino acid substitutions were seen at positions 41, 90, 98, 103, 106, 108, 138, 181, 184, 190, 215, 
and 219, which confer high/intermediate levels of resistance to most RTIs, independently or together. Our 
results show that there is an urgent need to tailor ART drug regimens to the individual to achieve optimum 
therapeutic outcome in North India.
Ong, LY. et 
al. [25]
Journal of 
Medical 
Virology
. Plasma specimens from N=100 HIV+ HAARTnaïve 
adult were collected between March 2008 and 
August 2010.
Transmitted drug resistance prevalence among HAART-naïve patients was low in this cohort of patients in 
Kuala Lumpur despite introduction of HAART 5 years ago. Owing to the high genetic diversity, continued 
molecular surveillance can identify the persistent emergence of HIV-1 URF and novel CRF with significant 
epidemiological impact. 
Santoro, 
MM. Et al. 
[28]
Clinical 
Infectious 
Diseases
The genotyping success rate was evaluated in 12 
828 human immunodeficiency virus type 1 (HIV-1) 
plasma samples with viremia >50 copies/mL, tested 
using the commercial ViroSeq HIV-1 Genotyping 
System or a homemade system.
In patients failing cART with LLV, HIV-1 genotyping provides reliable and reproducible results that are 
informative about emerging drug resistance. 
Abdissa, A. 
et al. [31]
BMC 
Infectious 
Diseases
Two hundred sixty five patients had VL data 
available at baseline and at 6 months.
Our data confirm that the currently recommended first-line ART regimen is efficient in the vast majority 
of individuals initiating therapy in Jimma, Ethiopia eight years after the introduction of ART. However, the 
documented occurrence of transmitted resistance and accumulation of acquired HIVDR mutations among 
failing patients justify increased vigilance by improving the availability and systematic use of VL testing to 
monitor ART response, and underlines the need for rapid, inexpensive tests to identify the most common 
drug resistance mutations. 
Phanuphak, 
P. et al. [32]
Journal of 
Acquired 
Immune 
Deficiency 
Syndromes
1471 Asian treatment-naive patients. TDR was associated with failure in the context of non-fully sensitive regimens. Efforts are needed to 
incorporate resistance testing into national treatment programs. 
Lambert-
Niclot, S. et 
al. [38]
Journal of 
Antimi-
crobial 
Chemo-
therapy
Two groups of patients: the first group (n = 998) 
failing a nucleoside reverse transcriptase inhibitor 
(NRTI) plus boosted protease inhibitor (PI)-based 
regimen and the second group (n = 3733) failing 
an NRTI plus non-nucleoside reverse transcriptase 
inhibitor (NNRTI)-based regimen.
In patients failing an NRTI plus NNRTI-based regimen, to know the feasibility of a switch to rilpivirine/
emtricitabine/tenofovir disoproxil fumarate, reliable resistance information should be available at the time of 
use of concurrent NNRTI therapy. 
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Journal Sample Sample Study Particularities
Mulu, A. et 
al. [39]
BMC 
Infectious 
Diseases
Viral RNA was determined in 160 baseline plasma 
samples.
Strong evidence for consistent HIV-1C clade homogeneity and low influx of other variant into the country 
was found. The level of drug resistance observed in chronically infected treatment naïve patients which 
exceeds the WHO estimates suggests the need for incorporation of HIV-1 drug resistance testing prior to ART 
initiation. The occurrence of monophyletic transmission clusters affecting (24/160) individuals indicates their 
potential risk related practice. Thus, an intensified public health intervention program and monitoring of HIV 
drug resistance testing appears indispensable. 
Azam, M. et 
al. [40]
Journal of 
Infection in 
Developing 
Countries
Fifty-four HIV-1 strains isolated from treatmentnaive 
patients (n = 54) were included in this study.
This study confirms that HIV-1 subtype C predominates in northern India. Protease secondary mutations 
associated with drug resistance to protease inhibitors (PIs) were present with high frequency in the HIV-1 C 
subtype strains isolated from north Indian ARV treatment-naive patients, but no primary resistance mutations 
were found in this region. 
Ross, LL. et 
al. [41]
PLoS ONE Viral transmission clusters (VTCs) were initially 
predicted from a phylogenetic analysis of 
population level HIV-1 pol sequences obtained 
from 690 antiretroviral-naïve subjects in 2007.
Our analysis shows specific geographical and drug resistance trends that correlate well with transmission 
clusters defined by HIV sequences of similarity. Furthermore, our study demonstrates the utility of molecular 
and epidemiological analysis of VTCs for identifying population-specific risks associated with HIV-1 
transmission and developing effective local healthcare strategies. 
Vande-
nhende, 
M-A. et al. 
[42]
PLoS ONE Twenty-nine ART-naive patients followed up in the 
ANRS-CO3 Aquitaine Cohort.
Low frequency DRMs detected before ART initiation and at VF in patients experiencing VF on first-line ART 
can increase the overall burden of resistance to PI, NRTI and NNRTI. 
Antunes 
DA. et al. 
[44]
PLoS One. Bioinformatics tools were used to evaluate the 
impact of the unusual mutations D30V and V32E 
over the dynamics of the PR-Nelfinavir complex.
The D30V mutation triggered a subtle change in the PR structure, which was also observed for the well-
known.
Nelfinavir resistance mutation D30N, while the V32E exchange presented a much more dramatic impact over 
the PR flap dynamics. 
Xiaobai Z. et 
al. [45]
PLoS One. Deep sequencing was performed on samples from 
90 ART-naïve subjects.
ART-naïve subjects from Hunan Province China infected predominantly with subtype AE frequently possessed 
HIV variants with WHO NRTI/NNRTI TDRs by deep sequencing that would affect the first line ART used in the 
region. 
Johnston, V. 
et al. [46]
Journal of 
Infectious 
Diseases
Using prospectively collected data from patients in 
South Africa(417).
No adherence, suggested by subtherapeutic ART with/without major resistance mutations, significantly 
contributed to failure when switching regimen. Unresolved no adherence, not NRTI resistance, drives early 
second-line failure. 
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Journal Sample Sample Study Particularities
Mata-
Munguía, C. 
et al. [47]
BMC 
Bioinfor-
matics
Protease sequences isolated from 151 Mexican 
HIV-1 patients that were naïve to, or subjected to 
antiretroviral therapy, were examined.
 The structural correlation of natural polymorphisms and unusual mutations with drug resistance is useful 
for the identification of HIV-1 variants with potential resistance to PIs. The D29V mutation likely confers a 
selection advantage in viruses; however, in silico, presence of this mutation results in unstable enzyme/PI 
complexes, that possibly induce resistance to PIs. 
Megens, S. 
et al. [48]
Virology Origin and the effect of insertion D67D-
THGERDLGPA within HIV-1 RT from a patient failing 
antiviral therapy.
These results suggest that a particular sequence within human chromosome 17 is prone to horizontal 
gene transfer into the HIV-1 RT finger subdomain. This insertion confers selective advantage to HIV-1 by its 
contribution to multi-drug resistance and restoration of impaired replication capacity. 
Ibrahim, Y. 
et al. [55]
Malaysian 
Journal 
of Public 
Health 
Medicine
A health facility-based cross sectional study 
conducted among adults' people living with HIV in 
Omdurman HIV/AIDS centre, Sudan.
Educational level and social support against HIV-related stigma and discrimination were not significantly 
associated with adherence. Adherence to antiretroviral therapy among the respondents is very poor. Urgent 
interventions based on modifiable factors and mainly targeting females and younger age group are needed 
to improve adherence to antiretroviral therapy among people living with HIV. 
Bulteel, N. 
et al. [66]
Journal of 
Infection
5455 patients received either (or both) 3TC, TDF 
and EFV or FTC, TDF and EFV contributing 6465 
treatment episodes over 9962 person-years follow 
up.
We have not found evidence of an increased risk of development of M184V and K65R in patients exposed to 
3TC. 
Choi, J-Y. et 
al. [67]
Journal 
of Clinical 
Virology
The amplified HIV-1 pol gene in 535 patients 
requested for genotypic drug resistance testing 
from 2004 to 2009 by the Korea Centers for 
Disease Control and Prevention was sequenced and 
analyzed annually and totally.
About 50% and less than 10% of patients infected with HIV-1 have multidrug and multiclass resistance 
linked to 16 antiretroviral drugs, respectively. The significance of this study lies in its larger-scale examination 
of the prevalence of drug resistant variants and multidrug resistance in HAART experienced patients in South 
Korea. 
Abbreviations:  ART = antiretroviral treatment, TDR = transmitted drug resistance, SHCS = swiss HIV cohort study, DRDB = drug resistance database, HIV= human immunodeficiency 
virus, cART = combination antiretroviral therapy, NNRTI = non nucleoside reverse transcriptase inhibitor, NRMV = Non-nucleoside reverse transcriptase inhibitor 
resistant virus present in majority vírus, DRM = drug resistance mutations, IQR = interquartile range, RTI = reverse transcriptase inhibitors, HAART = Highly active 
antiretroviral therapy, URF = unique recombinant forms, CRF = circulating recombinant form, LLV = low-level viremia, V L= viral load, HIVDR = HIV drug resistance, 
NRTI = nucleoside reverse transcriptase inhibitor, RNA= ribonucleic acid, WHO = World Health Organization, PI = protease inhibitors, ARV = antiretroviral,  
VTC = viral transmission cluster, ANRS = Agence Nationale de Recherche sur le Sida, VF= virological failure, PR= protease, 3TC = Lamivudine, FTC = emtricitabine, 
TDF = tenofovir, EFV= efavirenz.
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used during the data analysis process. Study designs 
included 1 descriptive study, [45] 7 cross sectional 
studies [10, 17, 19, 44, 47, 55, 68] and 19 cohort 
studies. [1, 7, 8, 15, 21, 25, 28, 31, 32, 38-40, 41, 
42, 46, 48, 66, 67, 82] 
Discussion
The increased use of antiretroviral therapy has re-
duced significantly the number of deaths related 
to HIV/AIDS and improved the life expectancy of 
people living with HIV. [10] It has been suggested 
that scaling up of ART results in a level of virological 
suppression at the population level that will reduce 
HIV transmission. [11-15] With the increased num-
bers of patients being treated, there is increased 
potential for development and spread of resistant 
virus. Individuals infected with HIV acquire antiretro-
viral resistance in one of two ways: (1) transmitted 
drug resistance (TDR) occurs when antiretroviral-
naive individuals are infected with viruses already 
harboring resistance mutations, and (2) acquired 
drug resistance (ADR) emerges from the selective 
pressure of antiretrovirals in individuals without fully 
suppressed viral loads either because of poor adhe-
rence or the use of a non-suppressive regimen. [16, 
17] As access to antiretroviral therapy (ART) expands 
in resource-limited countries, concerns will increase 
regarding the numbers of patients failing treatment 
and the subsequent emergence of drugresistant vi-
ruses. Resistant virus selected during treatment may 
subsequently be transmitted to newly infected indi-
viduals, undermining the effectiveness of currently 
recommended or available first-line ART. [18, 19] 
Also, factors associated with the development of 
drug resistance include poor adherence, suboptimal 
ART doses, and initiation of therapy late in the cour-
se of HIV infection. [20, 21] 
Highly active antiretroviral therapy (HAART) has 
been shown to reduce significantly the mortality 
and morbidity of patients infected with HIV at va-
rious disease stages. [2, 22-25] Although HAART 
may limit the extent of selection during treatment, 
the success of HAART could still be compromised 
by the emergence of HIV drug resistance. [10, 26] 
Resistance can be acquired as the pool of variants 
within the population increases. [19] Resistance to 
an antiretroviral drug class is defined by the pre-
sence of at least one primary resistance mutation 
(PRM), as included in the mutation list paneled 
by the International Antiviral Society in 2013 [27], 
within the genes for the nucleos(t)ide reverse trans-
criptase inhibitors (NRTIs), non nucleos(t)ide reverse 
transcriptase inhibitors (NNRTIs), and protease inhi-
bitors (PIs). [28] 
Viral replication under suboptimal antiretroviral 
pressure leads to accumulation of resistance mu-
tations. As the number of mutants increases, fu-
ture therapeutic choices become more limited [29] 
especially with regard to monotherapy. In addi-
tion, mutations conferring resistance to one drug 
frequently confer cross resistance to other antire-
troviral drugs within the same class. [30, 31] The 
significance of drug-specific or drug class-specific 
transmitted drug resistance to treatment outcome 
is not fully understood, especially when one or 
more drugs or drug classes in the regimen are still 
effective. [32] 
Non nucleoside reverse transcriptase inhibitors 
(NNRTIs) are important and common components 
of highly active antiretroviral therapy (HAART). Rilpi-
virine, a second-generation NNRTI, is active against 
wild-type viruses and retains activity against some 
NNRTI-resistant HIV-1 strains. [33-35] This drug is 
currently indicated in the USA and Europe in com-
bination with other antiretroviral drugs for the 
treatment of antiretroviral-naive HIV-1-infected pa-
tients with (HIV-1 RNA≤100000 copies/mL). [36] 
Rilpivirine resistance-associated mutations (RAMs) 
were defined as K101E/P, E138A/G/K/Q/R, V179L, 
Y181C/I/V, Y188L, H221Y, F227C and M230I/L. 
[27, 36] According to an algorithm developed by a 
national agency for AIDS research (ANRS), rilpiviri-
ne resistant strains were defined as having at least 
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one mutation among K101E/P, E138A/G/K/ Q/R/S, 
V179L, Y181C/I/V, Y188L, H221Y and M230I/L/V or 
as having L100I+K103N. Although, rilpivirine is not 
recommended in patients failing an NNRTI regimen. 
[37-40] 
Ross et al. [41], in a phylogenetic analysis of HIV 
using population sequencing and ultra deep se-
quencing (UDS) data from 690 antiretroviral-naive 
HIV-infected subjects, observed 18 additional NNR-
TI, NRTI, and major PI resistance mutations. The 
authors detected a prevalence of between ≥ 1 and 
< 6% of which 12/18 (67%) were different types 
of NNRTI-related mutations (major: K101E, K103N, 
E138A, E138G, E138K; minor: K101E, V106I, E138A, 
E138G, E138K). The remaining 6/18 types of mu-
tations detected at low prevalence were major PI-
related mutations (D30N, M46I, M46L, V82A). The 
newly detected mutations that were observed in > 
1 viral genotype were the major PI mutations M46I 
(2 subjects) and V82A (2 subjects), and the reverse 
transcriptase (RT) mutation V106I (7 subjects). A to-
tal of 16 subjects had virus with NNRTI and major PI 
mutations detected by UDS that were not detected 
by population sequencing with the frequencies of 
< 6%. For the major PI-associated mutations, these 
were detected by UDS in virus from 6 subjects. The 
PI major mutations included D30N, 
M46I, M46L and V82A with the D30N and M46I 
mutations occurring in 2 separate samples from the 
same viral transmission cluster (VTC). For 10 viral 
samples from 8 VTCs, NNRTI mutations were de-
tected only by UDS and at frequencies of 6% and 
included K101E, K103N, V106I, E138A, E138G, and 
E138K. Nevertheless, Vandenhende et al. [42] found 
that accessory PI mutations are polymorphic, but 
their accumulation could impact the susceptibility 
to some PI such as Lopinavir or Nelfinavir. 
According to the International AIDS Society, 23 
mutations in 16 codons of the protease gene rela-
ting to major drug-resistance to PIs were identified 
by phenotypic resistance assays. [43, 44] Xiaobai 
et al. [45] identified PI TDR mutations by deep se-
quencing (24% of subjects), but these were found 
in isolation and at low variant frequency. The most 
frequent and highest HIV variant level identified 
was T74S in 10 subjects (11.5%). The low-level 
variants were interpreted by Stanford.hivdb.edu, 
9.2% of subjects had intermediate or high-level PI-
associated resistance (driven by V32I, I47V, G48V, 
I50V & V82A/T); with only 2% of subjects had 
HIV variants having multiple PI mutations. At an 
individual level, switching nonadherent patients to 
a boosted PI-based regimen that is less susceptible 
to development of resistance may be appropriate 
and is the recommended strategy in many high-in-
come settings. [46] Among the PIs, indinavir (IDV) 
demonstrated a higher affinity for mutant protease 
proteins. [47] 
High-level resistance to antiviral drugs generally 
arises by stepwise accumulation of mutations rather 
than insertions or deletions [27] but insertions and 
deletions contributing significantly to drug resis-
tance have been described. [48] Insertions of two 
amino acids have mainly been reported at RT posi-
tion 69 in clinical isolates from HIV-1 patients failing 
ART. These insertions typically confer NRTI resistan-
ce in association with thymidine analog mutations 
(TAMs). [49, 50-53] In Megens et al. [48], a virus 
strain without the insertion already displayed some 
NRTI resistance due to the TAM1 mutations and the 
level of resistance was strongly enhanced after the 
addition of the insertion. Surprisingly, NNRTI resis-
tance was observed in the absence of major NNRTI-
associated mutations and the level of resistance was 
further elevated after the selection of strains with 
K103N and Y181C mutations. [54] 
Ibrahim et al. [55] also showed, in a health facility-
based cross sectional study, that poor adherence 
to antiretroviral therapies could have serious conse-
quences for individuals who are infected with HIV 
including failure of prevention of viral replication, an 
increased possibility of developing viral resistance, 
the progression of the disease to stages of clini-
cal complications, and reduction of survival. [55-
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58] Factors associated with poor adherence based 
on the findings of this study include gender, age, 
employment, marital status, and health status. [55] 
The results reveal that females, younger people and 
unemployed individuals were more likely to be asso-
ciated with poor adherence to antiretroviral therapy. 
Lack of support from either the family or commu-
nity is also an important risk factor for poor adhe-
rence to antiretroviral therapy. [55] Moreover, low 
adherence to ART is associated with an increased 
risk of resistance to HIV-1 reverse transcriptase inhi-
bitors (RTIs). The emergence of drug resistant virus 
limits antiretroviral choice due to cross-resistance to 
other antiretroviral agents [59, 60] and is strongly 
associated with progression of HIV-1 infection and 
increased mortality. [61-66] 
Choi et al. [67] assumed that the earlier that pa-
tients were diagnosed and treated, the higher the 
level of drug resistance that would develop in them. 
Based on the treatment history of these patients, 
mutations giving resistance to the extensively used 
NRTIs were more prevalent than to PIs. [67] As the 
efficacy of the combination antiretroviral therapy 
(cART) decreased, the number of patients at risk to 
resistant virus increased with a possible concomitant 
increase in risk of TDR. [7] The consequences of pro-
longed continuation of non suppressive cART were 
observed in a cross-sectional study conducted by 
Mutwa et al. [68] Their genotypic results, with 90% 
of children with virologic failure and available geno-
typing determinations, showed the development of 
major NRTIs and NNRTI-associated resistance muta-
tions. [68-72] 
A major obstacle to the long-term efficacy of 
ART is the emergence of drug resistance mutations 
in the polymerase gene of HIV-1, the primary tar-
get for ART. This reduces anti-retroviral (ARV) drug 
susceptibility [73] and limits the therapeutic options 
of newly infected patients. [74] The transmission of 
resistant variants to uninfected individuals has be-
come a serious clinical and public-health concern. 
[73] Knowledge of prevalent drug resistant variants 
is useful for optimizing therapeutic schemes and ob-
taining a better patient response. [21, 75] Despite 
stable ART, many patients experience episodes of 
low-level viremia (LLV), defined as plasma viral load 
(pVL) measurements between 50 and 1000 HIV-1 
RNA copies/mL. This low level of virus production 
in the presence of ART increases the potential for 
mutants to arise and their selection. An increased 
risk of virologic failure has been associated with 
episodes of LLV in several studies, [74-79] but not 
in others. [80-82] Finally, it is important to expand 
the surveillance for antiretroviral resistance amongst 
these patients as well as treatment naive patients in 
order to facilitate the early detection of transmitted 
drug resistant strains to individual patients as well 
as the population. [25]. 
Conclusion 
Recent findings reveal that the development of re-
sistance to antiretroviral therapy by HIV-infected pa-
tients is associated with increased access to drugs 
used in the treatment, and with low adherence. The 
appearance of these resistant strains is associated 
with specific mutations that not only reduce the 
effect of the drug class in use on the patient but 
also provide the emergence of cross-resistance with 
other classes. Poor adherence to treatment, the use 
of sub-optimal doses and treatments initiated too 
late for efficacy provide conditions that allow the 
emergence of resistant mutations classes of drugs 
currently used in treatment of HIV/AIDS as NNRTIs, 
NRTIs and PI's and contribute to the reduction of 
effectiveness of treatment. 
Knowledge of the mutations that confer drug re-
sistance is useful for optimizing treatment regimens. 
Selection of resistant viruses by poor adherence to 
antiretroviral treatment and the acquisition of re-
sistant viruses are important factors for the failure 
of antiretroviral treatment. With knowledge of the 
prevalent mutations conferring resistance to the 
antiHIV drugs, alternative drugs can be used. As 
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such, it is necessary to continue the evaluation of 
mutations causing resistance to antiretroviral thera-
py and the development of more effective ways of 
managing HIV/AIDS. 
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